Immunogenicity of an Extended Dose Interval for the Ad26.ZEBOV, MVA-BN-Filo Ebola Vaccine Regimen in Adults and Children in the Democratic Republic of the Congo

During the 2018–2020 Ebola virus disease outbreak in Democratic Republic of the Congo, a phase 3 trial of the Ad26.ZEBOV, MVA-BN-Filo Ebola vaccine (DRC-EB-001) commenced in Goma, with participants being offered the two-dose regimen given 56 days apart. Suspension of trial activities in 2020 due to...

Full description

Saved in:

Bibliographic Details
Published in:	Vaccines Vol. 12; no. 8; p. 828
Main Authors:	Choi, Edward Man-Lik, Kasonia, Kambale, Kavunga-Membo, Hugo, Mukadi-Bamuleka, Daniel, Soumah, Aboubacar, Mossoko, Zephyrin, Edwards, Tansy, Tetsa-Tata, Darius, Makarimi, Rockyath, Toure, Oumar, Mambula, Grace, Brindle, Hannah, Camacho, Anton, Connor, Nicholas E., Mukadi, Pierre, McLean, Chelsea, Keshinro, Babajide, Gaddah, Auguste, Robinson, Cynthia, Luhn, Kerstin, Foster, Julie, Roberts, Chrissy h., Johnson, John Emery, Imbault, Nathalie, Bausch, Daniel G., Grais, Rebecca F., Watson-Jones, Deborah, Muyembe-Tamfum, Jean Jacques
Format:	Journal Article
Language:	English
Published:	Switzerland MDPI AG 23.07.2024 MDPI
Subjects:	Adenoviruses Adolescents Adults Age groups Antibodies Children Consortia COVID-19 COVID-19 vaccines Democratic Republic of the Congo DRC Ebola Ebola virus Ebolavirus Enzyme-linked immunosorbent assay Epidemics Glycoproteins Hypothesis testing Immunization Immunogenicity Immunoglobulin G Laboratories Medicine outbreak Pandemics Public health R Sample size Teenagers vaccine Vaccines Viral diseases Viruses Ankara Turkey Turkey Belgium Congo-Democratic Republic of Congo United States > US San Juan Capistrano California vaccine DRC Mvabea Zabdeno Ad26.ZEBOV MVA-BN-Filo outbreak interval Democratic Republic of the Congo Ebola immunogenicity
ISSN:	2076-393X, 2076-393X
Online Access:	Get full text
Tags:	Add Tag No Tags, Be the first to tag this record!

Be the first to leave a comment!